BioSpace News Archive

ChromaDex Corp. announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today reports additional positive data from its six-month double-blind Phase 2b PARADIGM trial of NeuroSense’s lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (“ALS”).

Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2024 Animal Health Summit on Thursday, February 29, 2024.

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals.

Odne Inc. is thrilled to announce the appointment of Jeff Durrbeck as the President of US Operations.

Mabwell recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology.

jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell ® for Retinitis Pigmentosa in the Second Half of 2024.

Hyperfine, Inc. and Athletic Heart Cardiac and Metabolic Testing, LLC announced a collaboration to bring portable brain imaging screenings to current and retired professional athletes, starting with retired professional basketball players.

Saghmos Therapeutics, Inc. announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.

IMBiotechnologies Ltd. is pleased to announce the signing of a supply agreement with Embol Experts, LLC, one of the largest group purchasing organizations in the US, supplying office-based laboratory and ambulatory surgical center clinics focused on minimally-invasive procedures.